Hi everyone, Seemingly slow news week. Could be a function of the time of year. In this edition, we delve into the setbacks in AIM's Ampligen Phase II trial, the reliance on private funding for long COVID research, and the potential breakthroughs in treating long COVID through amino acid deficiencies. We also explore the duration of COVID-19 in the body, predictors of non-recovery from fatigue and cognitive deficits, the effects of pulmonary rehabilitation, and much more.
Thanks so much for this info, Brandon!
Clinicaltrials.gov has a list of me/cfs research and their status. I hope that helps!
I’m concerned that they keep using the 6 minute walk test as the clinical endpoint, when that isn’t relevant for post exertional malaise.